News sentiment analysis powered by sentiment-insight.com
Pune-based Serum Institute to soon start Phase I & II trials of dengue vaccine in India
After a successful Phase-I trial of the dengue vaccine in Australia, the Serum Institute of India (SII) will soon begin Phase I and Phase II trials for its Dengusiil vaccine in India. The vaccine is likely to be rolled out in the market by 2027, if clinical trials are completed with timely approvals.
Billionaire Cyrus Poonawalla Suffers Cardiac Arrest, Stable After Angioplasty Poonawalla, 82, suffered a cardiac arrest on Thursday. He is Chairman and Managing Director of the city-based vaccine manufacturer Serum Institute of India (SII)
Malaria gets its second vax: Why it’s momentous | Mint A malaria vaccine developed by Oxford University and Serum Institute of India (SII) has been recommended for large-scale use by the World Health Organization. The R21/Matrix-M has shown up to 75% efficacy. The vaccine is expected to be available globally in mid-2024.
Sprott: Q2 Earnings Snapshot Sprott Inc. (SII) on Wednesday reported earnings of $17.7 million in its second quarter. The company posted revenue of $50.6 million in the period.
Centre Launches Study In India Portal For International Students. Details Inside Home EducationCentre Launches Study In India Portal For International Students. The SII programme seeks to endorse India as a prime education hub for international students. The new portal will provide an integrated one-stop solution for student registration and visa application process.
MoU signed for infectious diseases, pandemic preparedness centre The infectious diseases and pandemic preparedness centre will act as a hub for training and capacity building. The idea for the centre was conceptualised during a meeting between Industries and IT Minister K. T. Rama Rao and SII CEO Adar Poonawalla in May 2022.
MoU signed for infectious diseases, pandemic preparedness centre The infectious diseases and pandemic preparedness centre will act as a hub for training and capacity building. The idea for the centre was conceptualised during a meeting between Industries and IT Minister K. T. Rama Rao and SII CEO Adar Poonawalla.
SII’s multivalent meningococcal meningitis vaccine gets WHO prequalification The Serum Institute of India (SII) said its vaccine to protect against the five predominant causes of meningococcal meningitis in Africa has been prequalified by the World Health Organisation. The MenFive vaccine has been developed through a 13-year collaboration between the Serum institute and PATH, a global nonprofit.
Those who invested in Sprott (TSE:SII) five years ago are up 60% The share price of Sprott Inc. (TSE:SII) has fallen 14% in the last quarter. The stock is up over five years, but its return of 36% is below the market return of 46%. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance.
RIL tops list of Indian companies, Serum Institute first among unlisted: Report Reliance Industries Limited (RIL), led by Mukesh Ambani, has emerged as the most valuable private sector company in India. Serum Institute of India (SII), helmed by Adar Poonawalla and renowned for its Covid-19 vaccines, takes the title of India's most valuable unlisted company. The report is based on the data from October 30, 2022 to April 30, 2023.
Bombay HC Directs 2 Influencers To Take Down 'Defamatory' Content Against SII, Its Covishield The Bombay High Court, in interim relief to Serum Institute of India (SII) its CEO and owner Adar Poonawalla, restrained two social media influencers and their organisations from posting ‘defamatory’ content about their COVID-19 vaccine ‘Covishield’ A single bench of Justice R I Chagla, also directed content creators Yohan Tengra and Ambar Kori to remove the “prima facie defamatory" about the side effects of the vaccine from Twitter and YouTube. The court will at a later date take up the company’s suit for the final hearing.
HC restrains 2 influencers from posting defamatory content against SII, Covishield The Bombay high court on Monday restrained two social media influencers from posting defamatory content against Serum Institute of India. The order was passed in an interim application filed by SII in a ₹100-crore defamation suit against influencers. SII had approached the HC in October 2022 claiming that Tengra and Koiri had initiated a smear campaign.
Bombay HC Directs 2 Influencers To Take Down 'Defamatory' Content Against SII, Its Covishield The Bombay High Court, in interim relief to Serum Institute of India (SII) its CEO and owner Adar Poonawalla, restrained two social media influencers and their organisations from posting ‘defamatory’ content about their COVID-19 vaccine ‘Covishield’ A single bench of Justice R I Chagla, also directed content creators Yohan Tengra and Ambar Kori to remove the “prima facie defamatory" about the side effects of the vaccine from Twitter and YouTube. SII filed a Rs 100 crore defamation suit in December 2022.
HC restrains 2 influencers from posting defamatory content against SII, Covishield The Bombay high court on Monday restrained two social media influencers from posting defamatory content against Serum Institute of India. The order was passed in an interim application filed by SII in a ₹100-crore defamation suit against influencers. SII had approached the HC in October 2022 claiming that Tengra and Koiri had initiated a smear campaign.
Bombay High Court gave THIS instruction to people who called Serum Institute, Adar Poonawalla 'murderers and c The Bombay High Court directed two individuals to delete online content posted by them and their organisations. A single bench of Justice R I Chagla temporarily restrained the two, Yohan Tengra from Anarchy for Freedom India, and Ambar Koiri from Awaken India Movement, from posting any content against the company. SII had filed a defamation suit against the two in December 2022.
Bombay HC restrains activists from posting defamatory content on SII, Covishield The Bombay high court restrained social media influencers from posting allegedly defamatory content about the Serum Institute of India. The order was passed in an interim application filed by SII in a defamation suit seeking ₹100 crore in damages. Yohan Tengra and Ambar Kori for allegedly posting objectionable content regarding Covishield.
Bombay HC restrains activists from posting defamatory content on SII, Covishield The Bombay high court restrained social media influencers from posting allegedly defamatory content about the Serum Institute of India. The order was passed in an interim application filed by SII in a defamation suit seeking ₹100 crore in damages. Yohan Tengra and Ambar Kori for allegedly posting objectionable content regarding Covishield.
HC finds posts against Serum Inst, Poonawala defamatory, orders it deleted The Bombay high court said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" A single bench of Justice R I Chagla also temporarily restrained them from posting any content against the company. The SII filed a defamation suit in December 2022 seeking damages to the tune of Rs 100 crore from the two individuals.
ED attaches Zavaray Soli Poonawalla’s assets worth ₹41.64 crore in Worli Zavaray Soli Poonawalla is brother of Serum Institute of India (SII) chairman and managing director Cyrus Poonwalla. The attached assets are in Ceejay House, Worli. The agency alleged that he and his family members misused the Liberalised Remittance Scheme.
‘Fema violation’ case: ED seizes ₹41.64cr assets of Pune bizman Zavareh Soli Poonawalla is brother of Serum Institute of India (SII) chairman and managing director Cyrus Poonsawalla. He and his family members were accused of misuse of the Liberalised Remittance Scheme under the provisions of the Foreign Exchange Management Act (FEMA), 1999.
Sign Up 
